CD8A and adenocarcinoma: Importantly, this combination therapy regimen effectively reduced the levels of p‐STAT3, p‐AKT, and immunosuppression marker (ARG‐1 protein) (Fig 7E) and up‐regulated CD8 expression in adenocarcinoma lesions.